|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/28/16 Orthofix Medical Inc. 10-Q 3/31/16 60:5.1M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 395K
2: EX-10.2 Material Contract HTML 61K
3: EX-10.3 Material Contract HTML 147K
4: EX-10.4 Material Contract HTML 122K
5: EX-10.5 Material Contract HTML 151K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
15: R1 Document and Entity Information HTML 40K
16: R2 Condensed Consolidated Balance Sheets HTML 88K
17: R3 Condensed Consolidated Balance Sheets HTML 32K
(Parenthetical)
18: R4 Condensed Consolidated Statements of Operations HTML 127K
and Comprehensive Income (Loss)
19: R5 Condensed Consolidated Statements of Cash Flows HTML 63K
20: R6 Nature of operations, basis of presentation and HTML 34K
recently issues accounting pronouncements
21: R7 Inventories HTML 48K
22: R8 Long-term debt HTML 24K
23: R9 Derivative instruments HTML 60K
24: R10 Fair value measurements HTML 181K
25: R11 Accumulated other comprehensive loss HTML 72K
26: R12 Earnings per share HTML 43K
27: R13 Share-based compensation HTML 27K
28: R14 Income taxes HTML 24K
29: R15 Business segment information HTML 115K
30: R16 Contingencies HTML 52K
31: R17 Share repurchase plan HTML 23K
32: R18 Nature of operations, basis of presentation and HTML 36K
recently issues accounting pronouncements
(Policies)
33: R19 Inventories (Tables) HTML 45K
34: R20 Derivative instruments (Tables) HTML 56K
35: R21 Fair value measurements (Tables) HTML 172K
36: R22 Accumulated other comprehensive loss (Tables) HTML 68K
37: R23 Earnings per share (Tables) HTML 40K
38: R24 Business segment information (Tables) HTML 110K
39: R25 Nature of operations, basis of presentation and HTML 21K
recently issues accounting pronouncements -
Additional Information (Detail)
40: R26 Inventories - Schedule of Inventories (Detail) HTML 32K
41: R27 Long-Term Debt - Additional Information (Detail) HTML 36K
42: R28 Derivative Instruments - Schedule of Fair Values HTML 29K
of Derivative Instruments (Detail)
43: R29 Derivative Instruments - Schedule of Gain (Loss) HTML 26K
Recognized in Other Comprehensive Income (Loss)
(Detail)
44: R30 Fair Value Measurements - Schedule of Financial HTML 54K
Assets and Liabilities Recorded at Fair Value on
Recurring Basis (Detail)
45: R31 Fair Value Measurements - Additional Information HTML 42K
(Detail)
46: R32 Fair Value Measurements - Schedule of HTML 29K
Reconciliation of Debt Securities (Detail)
47: R33 Accumulated Other Comprehensive Loss - Components HTML 46K
of Changes in Accumulated Other Comprehensive Loss
(Detail)
48: R34 Accumulated Other Comprehensive Loss - Components HTML 38K
of Changes in Accumulated Other Comprehensive Loss
(Parenthetical) (Detail)
49: R35 Earnings Per Share - Schedule of Reconciliation of HTML 30K
Weighted Average Shares Used in Calculation of
Basic and Diluted Net (Loss) Income Per Share
(Detail)
50: R36 Earnings Per Share - Additional Information HTML 29K
(Detail)
51: R37 Share-based Compensation - Additional Information HTML 32K
(Detail)
52: R38 Income Taxes - Additional Information (Detail) HTML 27K
53: R39 Business Segment Information - Additional HTML 21K
Information (Detail)
54: R40 Business Segment Information - Schedule of Net HTML 36K
Sales by SBU Reporting Segment (Detail)
55: R41 Business Segment Information - Summary of Net HTML 45K
Margin by SBU Reporting Segment (Detail)
56: R42 Contingencies - Additional Information (Detail) HTML 37K
57: R43 Share repurchase plan - Additional Information HTML 33K
(Detail)
59: XML IDEA XML File -- Filing Summary XML 99K
58: EXCEL IDEA Workbook of Financial Reports XLSX 49K
9: EX-101.INS XBRL Instance -- ofix-20160331 XML 1.20M
11: EX-101.CAL XBRL Calculations -- ofix-20160331_cal XML 112K
12: EX-101.DEF XBRL Definitions -- ofix-20160331_def XML 266K
13: EX-101.LAB XBRL Labels -- ofix-20160331_lab XML 637K
14: EX-101.PRE XBRL Presentations -- ofix-20160331_pre XML 488K
10: EX-101.SCH XBRL Schema -- ofix-20160331 XSD 108K
60: ZIP XBRL Zipped Folder -- 0001564590-16-016963-xbrl Zip 88K
Exhibit 31.1
CERTIFICATION
I, Bradley R. Mason, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q for the quarterly period ended March 31, 2016, of Orthofix International N.V.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a. |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b. |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c. |
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d. |
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has material affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
a. |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
b. |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Dated: April 28, 2016 |
By: |
|
/s/ BRADLEY R. MASON |
|
|
Name: |
|
|
|
|
Title: |
|
President and Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/28/16 | 8-K | ||
| For Period end: | 3/31/16 | |||
| List all Filings | ||||